<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03887806</url>
  </required_header>
  <id_info>
    <org_study_id>7158</org_study_id>
    <nct_id>NCT03887806</nct_id>
  </id_info>
  <brief_title>Cost Effectiveness Analysis of an Ancillary Study of the REMOTEV Study</brief_title>
  <official_title>Efficacy Cost Analysis: Retrospective Study on the REMOTEV Study's Ancillary Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The implications of the medico-economic impact are essential in the choice of first-line
      therapists. The economic impact is an important criterion to recommend the privileged use of
      Direct Oral Anticoagulants (AOD) in first intention.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Anticipated">March 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cost-effectiveness analysis between 2 therapeutic strategies, Direct Oral Anticoagulants (Rivaroxaban) versus standard anticoagulant (AVK)</measure>
    <time_frame>The period from November 1st, 2013 to July 01, 2015 will be examined</time_frame>
    <description>Cost-effectiveness analysis between 2 therapeutic strategies: The costs related to each strategy are calculated taking into account the direct and indirect costs.</description>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Venous Thromboembolic Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with a diagnosis of MTEV: pulmonary embolism or deep vein thrombosis diagnosed by
        the diagnostic reference methods according to the recommendations
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Major patient whose age is ≥18 years

          -  Patient with a diagnosis of MTEV: pulmonary embolism or deep vein thrombosis diagnosed
             by the diagnostic reference methods according to the recommendations

          -  Major patient included in the REMOTEV registry

          -  Patient having accepted that his data recorded in the REMOTEV register be re-used for
             research and publication purposes

        Criteria of non-inclusion

          -  Refusal to participate in the REMOTEV register

          -  Patient who refused to have his data reused for research and publication purposes

          -  Pregnant woman

          -  Subjects under safeguard of justice Subject under guardianship or curatorship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique STEPHAN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Strasbourg, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique STEPHAN, MD, PhD</last_name>
    <phone>33.3.69.55.09.52</phone>
    <email>dominique.stephan@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elena-Mihaela CORDEANU, MD</last_name>
    <phone>33 3 69 55 15 20</phone>
    <email>elena-mihaela.cordeanu@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service Des Maladies Vasculaires - Hta - Nhc</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique STEPHAN, MD, PhD</last_name>
      <phone>33.3.69.55.09.52</phone>
      <email>Dominique.Stephan@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Elena-Mihaela CORDEANU, MD</last_name>
      <phone>33 3 69 55 15 20</phone>
      <email>elena-mihaela.cordeanu@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Dominique STEPHAN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena-Mihaela CORDEANU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabrina GARNIER KEPKA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sébastien GAERTNER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2019</study_first_posted>
  <last_update_submitted>March 21, 2019</last_update_submitted>
  <last_update_submitted_qc>March 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Venous</keyword>
  <keyword>Thromboembolic</keyword>
  <keyword>Direct Oral Anticoagulants</keyword>
  <keyword>AOD</keyword>
  <keyword>Cost analysis</keyword>
  <keyword>REMOTEV</keyword>
  <keyword>AVK</keyword>
  <keyword>Pulmonary embolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

